Navigation Links
Biopure Announces Date to Meet with UK's Medicines and Healthcare Products Agency
Date:5/2/2008

CAMBRIDGE, Mass., May 2 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that a meeting with the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) is scheduled for May 29, 2008 in the UK.

The purpose of the meeting is to clarify the issues outlined in a letter Biopure received in April 2008 from the United Kingdom's Commission on Human Medicines regarding the company's application for marketing authorization for Hemopure(R). The issues relate to quality, clinical efficacy, safety and the reliability of data monitoring and auditing of clinical trials. The letter stated that the Commission was "reassured" on a number of the questions raised in its initial comment letter, but indicated that both "major" and "other" pharmacological and clinical issues either were not yet resolved by the Company's submission made in November 2007 or were only resolved in part.

As Biopure previously announced on April 11, 2008, the MHRA found the Company's Pennsylvania manufacturing facility to be in general compliance with the principles and guidelines of good manufacturing practices as identified in the Commission Directives.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Biopure Operations Compliant With U.K. Manufacturing Guidelines
2. Biopure Appoints New Independent Auditor
3. Biopure Completes U.K. Regulatory Agency Inspection
4. Biopure Announces 2008 First Quarter Financial Results
5. Biopure Launches Updated Website
6. Biopure Announces Pricing of Equity Offering
7. Biopure Gives Update on Malaysia Joint Venture Discussions
8. Pulmo BioTech Announces Appointment of Chief Financial Officer
9. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
10. Solei Systems, Inc., Announces That the Company Is Now Publicly Traded
11. China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 21, 2013  Personal Genome Diagnostics Inc. (PGDx), ... methodologies and expertise in genomic analysis of defined ... collaboration with Blueprint Medicines.  PGDx is an innovator ... alterations in tumors, and Blueprint Medicines is an ... a genetically defined patient population. "This ...
(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...
(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... featured your top picks of 2005 stories based on readership ... stories you may have missed. , ,If you don't receive ... You'll be e-mailed all our new stories, twice a week, ... subscription here. , ,Next week well resume our normal ...
... death sentence. , ,Of the approximately 12,000 people who are ... within a year, and the rest within 3 years. The ... to remove the tumor and radiation treatment with the maximum ... low quality of life. Because of this, researchers are racing ...
... While the University of Wisconsin-Madison continues to make ... cultures announced over the weekend, things aren't going so ... , ,Hwang Woo-suk, a South Korean stem-cell researcher, ... accusations surfaced that he fabricated stem-cell research results. , ...
Cached Biology Technology:Radiology advance points way to non-invasive brain-cancer treatment 2Stem-cell controversies slow progress 2
(Date:5/22/2013)... of pollinating insects and wild plants have slowed in ... led by the University of Leeds and the Naturalis ... dramatic reductions in the diversity of species in Britain, ... , But the picture brightened markedly after 1990, with ... bees, hoverflies and wild plants. , Professor ...
(Date:5/21/2013)... for a long time that some creatures evolve more ... for plants. But it may be that height plays ... and the U. S. National Evolutionary Synthesis Center. ... in the journal Nature Communications , Lanfear and ... Drawing from a database of global patterns in plant ...
(Date:5/21/2013)... is increasingly being considered in the management of ... resource that can help them recognize and respond ... in their lives. , Place-Based Conservation: Perspectives ... by the Pacific Northwest Research Station,s Linda Kruger, ... conservation. The book is published by Springer Verlag ...
Breaking Biology News(10 mins):Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Small but speedy: Short plants live in the evolutionary fast lane 2
... 2009 -- Companies and communities trying to restore vegetation on ... stimulate growth according to new research published in the November ... Not all plants benefit from the use of fertilizers. In ... Ecology at Universit Laval, and two colleagues spent a summer ...
... apes are formed primarily to handle the most stressful ... performed at the National Institute of Standards and Technology ... about protecting its close evolutionary cousins, the food apes ... be included in conservation efforts. The interdisciplinary team, ...
... agreement in Copenhagen to fund reduced emissions from deforestation ... simultaneously target sites that are both carbon and biodiversity-rich. ... journal Conservation Letters , also warns of challenges ... Africa unless safeguards are followed. This is because ...
Cached Biology News:Fertilizer use not always helpful in revegetation efforts 2Among apes, teeth are made for the toughest times 2New report underlines multiple benefits but also new challenges to biodiversity-rich sites 2New report underlines multiple benefits but also new challenges to biodiversity-rich sites 3
... ImageXpressULTRA imaging system from Molecular ... confocal system for automated acquisition and ... cell-based screening. ImageXpressULTRA is powered ... for screening acquisition, image storage and ...
... Assay is an anchorage-independent growth assay in ... stringent assay for detecting malignant transformation of ... with carcinogens or carcinogen inhibitors) are cultured ... for 21-28 days. Following this incubation ...
... Imager delivers high resolution CCD confocal imaging ... effective optical package that fits on your ... combined with high quantum efficiency CCD cameras, ... recording at up to 100 fps. A ...
... blotting of E-PAGE Gels easier and more ... pad and several types of pre-cut pre-assembled ... cm x 13.5 cm E-PAGE Gels*. The ... designed for western transfer of proteins (Figure ...
Biology Products: